We are live on ! Find out more
RGNT icon

Regentis Biomaterials
RGNT

6 hedge funds and large institutions have $2.98M invested in Regentis Biomaterials in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more funds holding

Funds holding: 3 → 6 (+3)

85% more capital inflows, than outflows

Capital inflows: $1.69M | Capital outflows: $916K

5.68% more ownership

Funds ownership: 10.65% → 16.33% (+5.7%)

Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Rosalind Advisors
Rosalind Advisors
Ontario, Canada
+$1.28M
2
WAM
Warberg Asset Management
Illinois
+$248K
3
Jane Street
Jane Street
New York
+$124K
4
Renaissance Technologies
Renaissance Technologies
New York
+$38.1K
5
UBS Group
UBS Group
Switzerland
+$285

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$916K

RGNT Hedge Fund Activity: Q2 2026 in Review

6 of the 8,367 institutional investors tracked by Wall St. Rank reported a position in Regentis Biomaterials (RGNT) for Q2 2026, worth a combined $2.98M — up 77% from $1.69M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new RGNT positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Rosalind Advisors, adding an estimated $1.28M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $916K sold.

  • 6 institutional investors held Regentis Biomaterials (RGNT) as of Q2 2026, up from 3 in Q1 2026.
  • Funds reported $2.98M of Regentis Biomaterials stock for Q2 2026, up 77% quarter-over-quarter.
  • 4 funds opened new Regentis Biomaterials positions in Q2 2026 and 1 closed out, a net change of +3 holders.
  • The largest Regentis Biomaterials buyer in Q2 2026 was Rosalind Advisors, an estimated $1.28M added.
  • The largest Regentis Biomaterials seller in Q2 2026 was AIGH Capital Management, an estimated $916K sold.

Based on aggregated 13F filings for Q2 2026.